A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
| 対象疾患 | Melanoma |
|---|---|
| 相 | 第1/2相 |
| スポンサー | Jennerex Biotherapeutics |
| ステータス | 完了 |
| 参加者数 | 10 名 |
| 介入（薬剤） | JX-594 |
| 開始日 | 2007年2月 |
| 完了日 | 2008年2月 |
| 結果公開日 | 2026年7月27日 |
概要
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Number of Participants With Objective Response in Injected Tumor(s)
| Recombinant Vaccinia Virus JX-594 | 5 Participants with Stable disease |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)